Much anticipated FDA decision about psychedelics for PTSD ends with denial

Abstract

In a closely watched decision involving the use of psychedelic treatment and therapy to treat post-traumatic stress disorder (PTSD), the U.S. Food and Drug Administration (FDA) on Aug. 9 declined to approve the use of midomafetamine (MDMA)-assisted therapy for the disorder. The federal agency issued a Complete Response Letter (CRL) for MDMA-assisted therapy to its drug maker, Lykos Therapeutics.